Fight CRC Clinical Trial Finder
| NCT ID | Title | 阶段 | Date Added | 地点 | Prior IO Allowed | CRC-directed | Status | 药物 | 标签 |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT02668770 |
TitleIpilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies | 阶段
第 1 阶段
|
Date Added 2016-01-29 |
地点
Texas, United States
|
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
Ipilimumab, MGN1703 |
标签
MSS/ MMRp
|
| NCT ID NCT02617277 |
TitleSafety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours | 阶段
第 1 阶段
|
Date Added 2015-11-30 |
地点
Colorado, United States
Florida, United States Tennessee, United States |
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
AZD1775, MEDI4736 |
标签
MSS/ MMRp
|
| NCT ID NCT02608385 |
TitleStudy of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors | 阶段
第 1 阶段
|
Date Added 2015-11-18 |
地点
Illinois, United States
|
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
Pembrolizumab |
标签
MSS/ MMRp
|
| NCT ID VAPER |
TitleA study looking at using a vaccine and chemotherapy to treat advanced cancer | 阶段
第 1 阶段
|
Date Added 2015-11-17 |
地点 |
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
Celecoxib, Cyclophosphamide, imiquimod, vaccine |
标签
MSS/ MMRp
|
| NCT ID NCT02600949 |
Title治疗晚期胰腺癌或结直肠癌患者的个性化多肽疫苗 | 阶段
第 1 阶段
|
Date Added 2015-11-09 |
地点
Texas, United States
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
imiquimod, Pembrolizumab, Sotigalimab, Synthetic Tumor-Associated Peptide Vaccine Therapy |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT02537418 |
TitleDurvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens | 阶段
第 1 阶段
|
Date Added 2015-09-01 |
地点
加拿大
|
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
durvalumab, Tremelimumab, Imfinzi |
标签
MSS/ MMRp
|
| NCT ID NCT02499328 |
TitleStudy to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck | 阶段
Phase 1, Phase 2
|
Date Added 2015-07-16 |
地点
Alabama, United States
California, United States Colorado, United States Florida, United States Indiana, United States Massachusetts, United States Michigan, United States Montana, United States New Jersey, United States Ohio, United States Texas, United States Virginia, United States Washington, United States 比利时 德国 意大利 西班牙 英国 |
Prior IO Allowed 没有 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
AZD5069, AZD9150, MEDI4736, tremelimumab (treme) |
标签
MSS/ MMRp
|
| NCT ID NCT02484404 |
Title抗程序性死亡配体-1 Durvalumab抗体（MEDI4736）与奥拉帕利（Olaparib）和/或塞地拉尼（Cediranib）联合治疗晚期实体瘤和晚期或复发性卵巢癌、三阴性乳腺癌、肺癌、前列腺癌和结直肠癌的I/II期研究... | 阶段
Phase 1, Phase 2
|
Date Added 2015-06-29 |
地点
Maryland, United States
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Cediranib, durvalumab, Olaparib |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT02465060 |
TitleTargeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | 阶段
第二阶段
|
Date Added 2015-06-08 |
地点
Alabama, United States
Alaska, United States Arizona, United States Arkansas, United States California, United States Colorado, United States Connecticut, United States Delaware, United States District of Columbia, United States Florida, United States Georgia, United States Hawaii, United States Idaho, United States Illinois, United States Indiana, United States Iowa, United States Kansas, United States Kentucky, United States Louisiana, United States Maine, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States Mississippi, United States Missouri, United States Montana, United States Nebraska, United States Nevada, United States New Hampshire, United States New Jersey, United States New Mexico, United States New York, United States North Carolina, United States North Dakota, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States Rhode Island, United States South Carolina, United States South Dakota, United States Tennessee, United States Texas, United States Utah, United States Vermont, United States Virginia, United States Washington, United States West Virginia, United States Wisconsin, United States Wyoming, United States 关岛 波多黎各 |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Adavosertib, afatinib, Afatinib Dimaleate, Binimetinib, Capivasertib, Copanlisib, Copanlisib Hydrochloride, Crizotinib, Dabrafenib, Dabrafenib Mesylate, Dasatinib, Defactinib, Defactinib Hydrochloride, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Larotrectinib Sulfate, Nivolumab, Osimertinib, palbociclib, Pertuzumab, PI3K-beta Inhibitor GSK2636771, Relatlimab, Sapanisertib, Sunitinib Malate, Taselisib, Trametinib, Trastuzumab, Trastuzumab emtansine, Ulixertinib, Vismodegib |
标签
MSS/ MMRp
|
| NCT ID NCT02453620 |
TitleEntinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer | 阶段
第 1 阶段
|
Date Added 2015-05-25 |
地点
California, United States
Connecticut, United States Maryland, United States Pennsylvania, United States |
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
Entinostat, Ipilimumab, Nivolumab, Opdivo, Yervoy |
标签
MSS/ MMRp
|
